Clinical benefit, health priorities and economic evaluation lessons learnt with COVID-19 vaccine
Letter from Dr. Xavier Badia, EDS Director. [...]
Chronic liver disease-associated severe thrombocytopenia in Spain through Delphi method
Management of chronic liver disease-associated severe thrombocytopenia in Spain: [...]
Analysis of Orphan Drugs P&R criteria in Spain (2003-2019)
Impact of the therapeutic positioning report in the P&R process in Spain: an [...]
Acute myeloid leukaemia in Spain through Delphi method
Current status of acute myeloid leukaemia in Spain: Results from a Delphi study [...]
Burden of Carbapenem-Resistant Gram-Negative Infections in Spain
Determining the burden of infectious diseases caused by carbapenem-resistant gra [...]
MCDA Hemlibra® in haemophilia A without inhibitors
Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis [...]
MCDA inhaler device in COPD treatment
Is patients’ perspective incorporated when choosing an inhaler device for COPD t [...]
MCDA framework for Oncologic Treatments
Development of a Multicriteria Decision Analysis Framework for Evaluating and Po [...]
MCDA Hemlibra® in haemophilia A with inhibitors
Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis [...]
MCDA framework for Ophan Drugs in Spain
Development and validation of an MCDA framework for evaluation and decision-maki [...]